Ideaya Plans Accelerated Approval Filing Of Darovasertib On Positive Phase II/III Data
If approved, the combination of darovasertib and crizotinib would be the first therapy for patients with HLA-A2*02:01-negative metastatic uveal melanoma.
Scrip - April 13, 2026

Revolution’s First Phase III Daraxonrasib Data Further Boost RAS Specialist’s High Value
Median overall survival for oral RAS(ON) inhibitor daraxonrasib was 13.2 months in second-line pancreatic cancer versus 6.7 months for chemo, pushing Revolution’s share price to a new high.
Scrip - April 13, 2026

Allogene Highlights Potential For Cema-Cel In The Community Setting
The allogeneic CAR-T-focused biotech announced minimal residual disease results from a futility analysis of the ALPHA3 trial of cemacabtagene ansegedleucel in lymphoma.
Scrip - April 13, 2026

Regeneron Taps Telix For Radiopharma Pact
Deal Snapshot: Shares in Telix have risen after the Australian firm inked an potentially billion- dollar agreement with Regeneron to develop next-generation radiopharmaceutical therapies.
Scrip - April 13, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Trump’s 100% tariffs and pharma; US tariffs loom over US-approved Chinese drugs; Gilead’s Tubulis buy-out; a closer look at Neurocrine’s Soleno bid; and an analysis of Q1 M&A.
Scrip - April 13, 2026

ADEL Raises $33M In Pre-IPO Round After Major Sanofi Deal
The Korean bioventure’s oversubscribed pre-IPO financing followed a $1bn global licensing deal with Sanofi and is set to support a planned KOSDAQ listing by the end of this year.
Scrip - April 13, 2026

Middle East Crisis Has South Korea On Alert For Medical Product Shortages
South Korea's government and pharma industry are taking coordinated emergency steps to monitor and prevent possible shortages in drug and medical supplies which could arise from naphtha supply disruptions.
Medtech Insight - April 13, 2026

Treasury Whistleblower Rewards Program Furthers US Government Focus On Healthcare Fraud And Abuse
A new proposal from the US Treasury Department would allow whistleblowers who alert the government to certain financial crimes to collect 10%-30% of any monetary penalties collected, creating a new risk for healthcare firms – especially those with overseas business partners.
Medtech Insight - April 13, 2026

Stryker Says Cyberattack Will Affect First-Quarter 2026 Results
Stryker is back. Manufacturing, ordering and distribution are fully restored after the March 11 Handala cyberattack. But the financial damage to the first quarter is confirmed as material – and the full reckoning will arrive on April 30.
Medtech Insight - April 13, 2026

EU Data Act Brings Yet More Questions For Medtech
The EU’s Digital Omnibus has made some of medtech’s requested changes to the AI Act; now the sector hopes the same can happen with the Data Act.
Medtech Insight - April 13, 2026

MHRA’s Commatteo Points To Pivotal Period For AI Regulation And Airlock 3
£3.6m funding uplift helps UK’s groundbreaking AI Airlock program break out of annual financing constraints and help regulation keep pace with the unprecedented pace of AI advances.
Medtech Insight - April 13, 2026

Storm Of Interest Could Follow FTC Complaint Alleging False Income Claims By MLM Distributor
Stormy Wellington agrees to proposed settlement prohibiting her from making false and misleading income claims. She not only sells health, wellness and beauty products in MLM but also is an entrepreneur for helping women building their own wealth.
HBW Insight - April 14, 2026

Celltrion Sees Growth Opportunities As Lingering Uncertainty Over US Tariffs Is Resolved
As the US pharma tariff drama reached its culmination, Celltrion aims to lock down its domestic manufacturing capabilities as a future-proof strategy. Meanwhile, the Korean firm expands biosimilar prescription bases in the US and Europe.
Generics Bulletin - April 13, 2026

Apotex Breakthrough Sets Stage For Future Semaglutide Competition
Apotex has won the first US tentative approvals for generic Ozempic, covering all marketed semaglutide strengths. Although patents prevent near-term launch, the development highlights mounting generic momentum in the multi-billion-dollar GLP-1 market.
Generics Bulletin - April 13, 2026

Glenmark Breaks GSK Hold On Fluticasone Inhalers
Glenmark has launched the first US generic fluticasone inhaler with 180-day CGT exclusivity, breaking GSK’s monopoly on the market and introducing true competition in a segment previously commanded by an authorized generic.
Generics Bulletin - April 13, 2026

Alvotech Looks To Make Good On Two-Year Bet
Alvotech’s chairman Robert Wessman tells Generics Bulletin that the firm’s early move away from Phase III trials and focus on forward-looking product design is giving it a speed and cost advantage, as it prepares for key filings and first-wave entry in major biosimilar markets.
Generics Bulletin - April 13, 2026

Execs On The Move: March 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - April 13, 2026